ABP-201

ABP-201 is a next-generation tetravalent bispecific antibody designed to treat vascular diseases of the eye, specifically wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). It simultaneously targets and inhibits two key angiogenic growth factors—vascular endothelial growth factor (VEGF) and angiopoietin-2 (ANG-2)—which are involved in abnormal blood vessel formation, destabilization, leakage, and neovascularization in retinal diseases. By dual inhibition of VEGF and ANG-2 with high-affinity binding sites for each ligand on the same molecule, ABP-201 aims to provide more effective normalization of vasculature than current anti-VEGF therapies alone. Preclinical studies have shown that ABP-201 reduces neovascular lesion formation and vascular leakage at least as effectively as standard-of-care agents like aflibercept/Eylea. The drug is being developed by Abpro through its subsidiary AbMed; AstraZeneca holds a minority stake via legacy MedImmune intellectual property[1][3][4][5].